This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

RNATICS GmbH

Profile

RNATICS develops novel, first-in-class RNA therapeutics to target disease-causing, regulatory RNAs in macrophages. This innovative way of delivery through immune cells enables access to organs previously not accessible to RNA therapy offering tremendous therapeutic opportunities for multiple diseases.The most advanced drug candidate, RCS-21, is currently in development for the treatment by inhalation of patients with severe cases of viral respiratory infections, such as COVID-19.